SCHEMBL8291279

SCHEMBL8291279

COC(=O)c1cc(-c2ccc(/C=C3\C(=O)N(CCCO)C(=O)C(C#N)=C3C)o2)ccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.66
KMT2A Q03164 8/20 0.60
POLB P06746 7/20 0.60
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 6/20 0.60
L3MBTL1 Q9Y468 6/20 0.60
MEN1 O00255 5/20 0.60
MAPT P10636 5/20 0.60
RECQL P46063 4/20 0.60
HPGD P15428 3/20 0.60
MCL1 Q07820 2/20 0.60
TDP1 Q9NUW8 5/20 0.57
DNMT1 P26358 1/20 0.57
BLM P54132 1/20 0.57
APEX1 P27695 4/20 0.48
CTDSP1 Q9GZU7 3/20 0.48
MET P08581 1/20 0.48
NTSR1 P30989 1/20 0.46
GALK1 P51570 1/20 0.46
XPA P23025 7/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290432 0.93 ESR2 (0.72) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL14584108 0.91 ESR2 (0.62) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8290360 0.91 ESR2 (0.81) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8291312 0.90 KMT2A (0.72) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8290540 0.87 SIRT2 (0.51) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8291240 0.86 ESR2 (0.84) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL19419927 0.83 ESR2 (0.69) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8290629 0.81 ESR2 (0.57) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL14584255 0.81 SIRT2 (0.52) ESR2KMT2APOLBALDH1A1KDM4E
SCHEMBL8291187 0.81 ESR2 (0.49) ESR2KMT2APOLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases DNPEP, PREP, ANPEP ESR2 2544/4885KMT2A 3390/4885POLB 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.